A Y Bedikian

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma
    Agop Y Bedikian
    Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Am J Clin Oncol 34:603-10. 2011
  2. pmc Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
    Omar Eton
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, USA
    J Transl Med 8:9. 2010
  3. doi request reprint Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
    A Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 22:787-93. 2011
  4. doi request reprint A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Invest 27:756-63. 2009
  5. doi request reprint A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Melanoma Res 18:400-4. 2008
  6. doi request reprint Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 26:624-33. 2008
  7. doi request reprint Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival
    Agop Y Bedikian
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Immunotoxicol 5:201-7. 2008
  8. ncbi request reprint Allovectin-7 therapy in metastatic melanoma
    Agop Y Bedikian
    The University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology, 1515 Holcombe Blvd, Box 430, Houston, TX 77030, USA
    Expert Opin Biol Ther 8:839-44. 2008
  9. ncbi request reprint Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 430, Houston, TX 77030, USA
    J Clin Pharmacol 46:727-37. 2006
  10. ncbi request reprint Phase II evaluation of temozolomide in metastatic choroidal melanoma
    Agop Y Bedikian
    The University of Texas M D Anderson Cancer Center, Department of Melanoma Medical Oncology, Houston, Texas 77030, USA
    Melanoma Res 13:303-6. 2003

Detail Information

Publications35

  1. doi request reprint Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma
    Agop Y Bedikian
    Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Am J Clin Oncol 34:603-10. 2011
    ....
  2. pmc Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
    Omar Eton
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, USA
    J Transl Med 8:9. 2010
    ..We sought to investigate the feasibility, safety, and antitumor activity of HSPPC-96 vaccines prepared from tumor specimens of patients with metastatic melanoma...
  3. doi request reprint Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
    A Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 22:787-93. 2011
    ..In the present study, the efficacy and toxicity profiles of DHA-paclitaxel were compared with those of dacarbazine...
  4. doi request reprint A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Invest 27:756-63. 2009
    ..INO-1001 had a moderate clearance, volume of distribution and a relatively short terminal half-life. Myelosuppression and elevation of liver transaminases were dose-limiting toxicities (DLTs) of INO-1001 at 400 mg...
  5. doi request reprint A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Melanoma Res 18:400-4. 2008
    ..A phase 2 trial to further elucidate the efficacy and safety of VSLI in metastatic uveal melanoma is ongoing...
  6. doi request reprint Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 26:624-33. 2008
    ..S. < 2 and absence of visceral metastasis as favorable prognostic factors for long-term survival...
  7. doi request reprint Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival
    Agop Y Bedikian
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Immunotoxicol 5:201-7. 2008
    ..0004), respectively. Ten-year overall survival rates were 15% and 5% (p = 0.0001), respectively. We conclude from these studies that patients benefited more from biochemotherapy than other regimens...
  8. ncbi request reprint Allovectin-7 therapy in metastatic melanoma
    Agop Y Bedikian
    The University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology, 1515 Holcombe Blvd, Box 430, Houston, TX 77030, USA
    Expert Opin Biol Ther 8:839-44. 2008
    ..Allovectin-7 therapy is a form of active immunotherapy that aims at immunization of the host with substances designed to elicit an immune reaction that will eliminate or slow down the growth and spread of the cancer...
  9. ncbi request reprint Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 430, Houston, TX 77030, USA
    J Clin Pharmacol 46:727-37. 2006
    ..8%). Overall, VSLI exhibited a longer circulation half-life and higher area under the plasma concentration-time curve compared to conventional vincristine, whereas its route of elimination remained unchanged...
  10. ncbi request reprint Phase II evaluation of temozolomide in metastatic choroidal melanoma
    Agop Y Bedikian
    The University of Texas M D Anderson Cancer Center, Department of Melanoma Medical Oncology, Houston, Texas 77030, USA
    Melanoma Res 13:303-6. 2003
    ..The treatments were well tolerated. We conclude that, like DTIC, temozolomide at the dose and schedule studied in this trial is not effective for the control of metastatic melanoma of uveal origin...
  11. ncbi request reprint Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 430, Houston, Texas, USA
    Melanoma Res 14:63-6. 2004
    ..No grade 3 acute allergic reactions were observed. Paclitaxel given by short intravenous infusion is marginally active against previously treated non-choroidal melanoma...
  12. doi request reprint Biochemotherapy in patients with advanced head and neck mucosal melanoma
    Holly L Bartell
    The University of Texas Medical School at Houston, Houston, Texas, USA
    Head Neck 30:1592-8. 2008
    ..No systemic therapy regimen has been recognized as effective for metastatic mucosal melanoma of the head and neck. We retrospectively analyzed the effectiveness of biochemotherapy in patients with advanced head and neck mucosal melanoma...
  13. ncbi request reprint Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:596-603. 2004
    ..In the current study, the authors addressed the feasibility of increasing the doses of agents used in concurrent biochemotherapy...
  14. doi request reprint A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence
    Kevin B Kim
    Department of Melanoma Medical Oncology, M D Anderson Cancer Center, The University of Texas, Houston 77030, Texas, USA
    Melanoma Res 19:42-9. 2009
    ..86 and 0.45, respectively) between the two groups. Biochemotherapy is not more effective than IFN as adjuvant therapy for melanoma. These findings support early termination of this trial...
  15. doi request reprint The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma
    Chan Yoon
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Melanoma Res 20:43-7. 2010
    ....
  16. ncbi request reprint Prognostic factors for survival of patients treated systemically for disseminated melanoma
    O Eton
    Department of Melanoma Sarcoma, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:1103-11. 1998
    ..We sought to verify these staging criteria and to identify prognostic variables that could be used to evaluate the impact of systemic therapy on long-term survival during the prior decade...
  17. ncbi request reprint Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
    Agop Y Bedikian
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 24:4738-45. 2006
    ..We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma...
  18. ncbi request reprint A phase II trial of arsenic trioxide in patients with metastatic melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1687-92. 2005
    ..Arsenic trioxide induces growth inhibition and apoptosis in human melanoma cell lines. Therefore, a Phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with Stage IV melanoma...
  19. ncbi request reprint Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial
    Omar Eton
    Department Melanoma Sarcoma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:2045-52. 2002
    ..In this phase III trial, we compared the effects of chemotherapy (cisplatin, vinblastine, and dacarbazine [CVD]) with those of sequential biochemotherapy consisting of CVD plus interleukin-2 and interferon alfa-2b...
  20. pmc Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 66:1087-93. 2010
    ..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement...
  21. doi request reprint A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma
    Agop Y Bedikian
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA
    Melanoma Res 20:218-26. 2010
    ..6 months. In conclusion, these results indicate that high-dose Allovectin-7 seems to be an active, well-tolerated treatment for selected stage III/IV metastatic melanoma patients with injectable cutaneous, subcutaneous, or nodal lesions...
  22. doi request reprint GPNMB expression in uveal melanoma: a potential for targeted therapy
    Michelle D Williams
    Department of Pathology, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Melanoma Res 20:184-90. 2010
    ..Uveal melanoma, like cutaneous melanoma, commonly expresses GPNMB. Ongoing clinical trials of CDX-011 should be extended to patients with metastatic uveal melanoma to determine potential efficacy in this subset of patients with melanoma...
  23. pmc A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:4086-94. 2010
    ..The authors of this report conducted a phase 1 study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases...
  24. ncbi request reprint Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma
    Julie A Ellerhorst
    Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Anticancer Drugs 13:169-72. 2002
    ..We conclude that, in keeping with the general chemoresistance of melanoma, 9-NC at the dose and schedule studied in this trial is significantly toxic and is not active for metastatic melanoma of cutaneous or uveal origin...
  25. doi request reprint Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma
    Jade Homsi
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Melanoma Res 20:507-10. 2010
    ..Its efficacy in this disease is limited with 32% of patients achieving stable disease. Further evaluation of DHA-paclitaxel in combination with other chemotherapeutic agents and/or targeted agents may improve its antitumor activity...
  26. ncbi request reprint Biochemotherapy in patients with metastatic anorectal mucosal melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas 77030, USA
    Cancer 100:1478-83. 2004
    ..Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported...
  27. doi request reprint Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors
    Sanjay Gupta
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Am J Clin Oncol 33:474-80. 2010
    ..We evaluated response rates and survival durations after HACE in such patients and analyzed factors affecting their survival...
  28. doi request reprint Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients
    Jade Homsi
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 1515 Holcombe Building, Unit 430, Houston, TX 77030, USA
    Melanoma Res 19:238-42. 2009
    ..Further evaluation of DHA-paclitaxel in combination with other chemotherapy or targeted agents could be considered...
  29. ncbi request reprint Adjuvant irradiation for axillary metastases from malignant melanoma
    Matthew T Ballo
    Departments of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 52:964-72. 2002
    ..To evaluate the outcome and treatment-related toxicity for patients with axillary lymph node metastases from malignant melanoma treated with surgery and radiation, with or without systemic therapy...
  30. ncbi request reprint Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma
    Matthew T Ballo
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 20:4555-8. 2002
    ..To evaluate the outcome and toxicity of a sphincter-sparing treatment strategy in the management of patients with anal-rectal melanoma...
  31. doi request reprint Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 64:161-7. 2009
    ..In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin...
  32. pmc Phase II trial of imatinib mesylate in patients with metastatic melanoma
    K B Kim
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Cancer 99:734-40. 2008
    ..However, based on the characteristics of the responding tumour in our study, clinical activity of imatinib, specifically in patients with melanoma with certain c-kit aberrations, should be examined...
  33. ncbi request reprint Metastatic uveal melanoma therapy: current options
    Agop Y Bedikian
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int Ophthalmol Clin 46:151-66. 2006
  34. ncbi request reprint The role of taxanes in the treatment of metastatic melanoma
    Helen Gogas
    First Department of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11 527, Greece
    Melanoma Res 14:415-20. 2004
    ..Taxanes, both as single agents and in combinations, may be a treatment option for some patients with metastatic melanoma, especially in the second-line setting...
  35. ncbi request reprint Challenges of chemosensitivity testing
    Patrick Hwu
    Clin Cancer Res 12:5258-9. 2006